An oxidation-resistant, recombinant alpha-1 antitrypsin produced in Nicotiana benthamiana

David Z. Silberstein, Kalimuthu Karuppanan, Hnin Hnin Aung, Ching-Hsien Chen, Carroll E Cross, Karen A. McDonald

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Proteases and reactive oxygen species (ROS) have long been implicated in playing key roles in host tissue injury at sites of inflammation dominated by macrophage activations and/or neutrophil infiltrations. Imbalances between proteases/antiproteases and ROS/antioxidants are recognized to contribute to amplification of inflammatory-based host tissue injury. This has been especially well-documented in such respiratory tract diseases as chronic obstructive pulmonary disease, cystic fibrosis, and acute respiratory distress syndrome. Inflammation-related protease/ROS disequilibria are further confounded by recognition that proteases can increase ROS by several different mechanisms and that ROS can inactivate proteases. The major human antiprotease, alpha-1 antitrypsin (AAT), is dramatically inactivated by ROS. AAT deficiency is the most prevalent genetic predisposing factor leading to emphysema, a condition treated by replacement infusions of plasma-derived AAT (hAAT) at a cost of up to $200,000 per year per patient. An updated method for production of a plant-made recombinant AAT (prAAT) engineered for enhanced oxidation resistance compared to hAAT is presented. Plant-made recombinant AAT shows comparable antiprotease activity to hAAT, and retains full activity under oxidative conditions that would deactivate hAAT. Additionally, we show that prAAT has similar effectiveness in preventing neutrophil elastase-induced cell death in an in vitro human bronchial epithelial cell culture model. We conclude that prAAT is potentially a “biobetter” AAT product that could be made available to individuals with a wide spectrum of inflammatory disorders characterized by overly aggressive neutrophilic infiltrations.

Original languageEnglish (US)
Pages (from-to)303-310
Number of pages8
JournalFree Radical Biology and Medicine
Volume120
DOIs
StatePublished - May 20 2018

Fingerprint

alpha 1-Antitrypsin
Tobacco
Reactive Oxygen Species
Peptide Hydrolases
Oxidation
Protease Inhibitors
Pulmonary diseases
Infiltration
alpha 1-Antitrypsin Deficiency
Tissue
Inflammation
Respiratory Tract Diseases
Leukocyte Elastase
Macrophage Activation
Neutrophil Infiltration
Macrophages
Adult Respiratory Distress Syndrome
Emphysema
Wounds and Injuries
Oxidation resistance

Keywords

  • Affinity purification
  • Alpha-1 antitrypsin
  • Elastase
  • HBE cell culture
  • Oxidation resistance
  • Transient expression

ASJC Scopus subject areas

  • Biochemistry
  • Physiology (medical)

Cite this

An oxidation-resistant, recombinant alpha-1 antitrypsin produced in Nicotiana benthamiana. / Silberstein, David Z.; Karuppanan, Kalimuthu; Aung, Hnin Hnin; Chen, Ching-Hsien; Cross, Carroll E; McDonald, Karen A.

In: Free Radical Biology and Medicine, Vol. 120, 20.05.2018, p. 303-310.

Research output: Contribution to journalArticle

Silberstein, David Z. ; Karuppanan, Kalimuthu ; Aung, Hnin Hnin ; Chen, Ching-Hsien ; Cross, Carroll E ; McDonald, Karen A. / An oxidation-resistant, recombinant alpha-1 antitrypsin produced in Nicotiana benthamiana. In: Free Radical Biology and Medicine. 2018 ; Vol. 120. pp. 303-310.
@article{c0cb267bd35e485184a964326c89b7a5,
title = "An oxidation-resistant, recombinant alpha-1 antitrypsin produced in Nicotiana benthamiana",
abstract = "Proteases and reactive oxygen species (ROS) have long been implicated in playing key roles in host tissue injury at sites of inflammation dominated by macrophage activations and/or neutrophil infiltrations. Imbalances between proteases/antiproteases and ROS/antioxidants are recognized to contribute to amplification of inflammatory-based host tissue injury. This has been especially well-documented in such respiratory tract diseases as chronic obstructive pulmonary disease, cystic fibrosis, and acute respiratory distress syndrome. Inflammation-related protease/ROS disequilibria are further confounded by recognition that proteases can increase ROS by several different mechanisms and that ROS can inactivate proteases. The major human antiprotease, alpha-1 antitrypsin (AAT), is dramatically inactivated by ROS. AAT deficiency is the most prevalent genetic predisposing factor leading to emphysema, a condition treated by replacement infusions of plasma-derived AAT (hAAT) at a cost of up to $200,000 per year per patient. An updated method for production of a plant-made recombinant AAT (prAAT) engineered for enhanced oxidation resistance compared to hAAT is presented. Plant-made recombinant AAT shows comparable antiprotease activity to hAAT, and retains full activity under oxidative conditions that would deactivate hAAT. Additionally, we show that prAAT has similar effectiveness in preventing neutrophil elastase-induced cell death in an in vitro human bronchial epithelial cell culture model. We conclude that prAAT is potentially a “biobetter” AAT product that could be made available to individuals with a wide spectrum of inflammatory disorders characterized by overly aggressive neutrophilic infiltrations.",
keywords = "Affinity purification, Alpha-1 antitrypsin, Elastase, HBE cell culture, Oxidation resistance, Transient expression",
author = "Silberstein, {David Z.} and Kalimuthu Karuppanan and Aung, {Hnin Hnin} and Ching-Hsien Chen and Cross, {Carroll E} and McDonald, {Karen A.}",
year = "2018",
month = "5",
day = "20",
doi = "10.1016/j.freeradbiomed.2018.03.015",
language = "English (US)",
volume = "120",
pages = "303--310",
journal = "Free Radical Biology and Medicine",
issn = "0891-5849",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - An oxidation-resistant, recombinant alpha-1 antitrypsin produced in Nicotiana benthamiana

AU - Silberstein, David Z.

AU - Karuppanan, Kalimuthu

AU - Aung, Hnin Hnin

AU - Chen, Ching-Hsien

AU - Cross, Carroll E

AU - McDonald, Karen A.

PY - 2018/5/20

Y1 - 2018/5/20

N2 - Proteases and reactive oxygen species (ROS) have long been implicated in playing key roles in host tissue injury at sites of inflammation dominated by macrophage activations and/or neutrophil infiltrations. Imbalances between proteases/antiproteases and ROS/antioxidants are recognized to contribute to amplification of inflammatory-based host tissue injury. This has been especially well-documented in such respiratory tract diseases as chronic obstructive pulmonary disease, cystic fibrosis, and acute respiratory distress syndrome. Inflammation-related protease/ROS disequilibria are further confounded by recognition that proteases can increase ROS by several different mechanisms and that ROS can inactivate proteases. The major human antiprotease, alpha-1 antitrypsin (AAT), is dramatically inactivated by ROS. AAT deficiency is the most prevalent genetic predisposing factor leading to emphysema, a condition treated by replacement infusions of plasma-derived AAT (hAAT) at a cost of up to $200,000 per year per patient. An updated method for production of a plant-made recombinant AAT (prAAT) engineered for enhanced oxidation resistance compared to hAAT is presented. Plant-made recombinant AAT shows comparable antiprotease activity to hAAT, and retains full activity under oxidative conditions that would deactivate hAAT. Additionally, we show that prAAT has similar effectiveness in preventing neutrophil elastase-induced cell death in an in vitro human bronchial epithelial cell culture model. We conclude that prAAT is potentially a “biobetter” AAT product that could be made available to individuals with a wide spectrum of inflammatory disorders characterized by overly aggressive neutrophilic infiltrations.

AB - Proteases and reactive oxygen species (ROS) have long been implicated in playing key roles in host tissue injury at sites of inflammation dominated by macrophage activations and/or neutrophil infiltrations. Imbalances between proteases/antiproteases and ROS/antioxidants are recognized to contribute to amplification of inflammatory-based host tissue injury. This has been especially well-documented in such respiratory tract diseases as chronic obstructive pulmonary disease, cystic fibrosis, and acute respiratory distress syndrome. Inflammation-related protease/ROS disequilibria are further confounded by recognition that proteases can increase ROS by several different mechanisms and that ROS can inactivate proteases. The major human antiprotease, alpha-1 antitrypsin (AAT), is dramatically inactivated by ROS. AAT deficiency is the most prevalent genetic predisposing factor leading to emphysema, a condition treated by replacement infusions of plasma-derived AAT (hAAT) at a cost of up to $200,000 per year per patient. An updated method for production of a plant-made recombinant AAT (prAAT) engineered for enhanced oxidation resistance compared to hAAT is presented. Plant-made recombinant AAT shows comparable antiprotease activity to hAAT, and retains full activity under oxidative conditions that would deactivate hAAT. Additionally, we show that prAAT has similar effectiveness in preventing neutrophil elastase-induced cell death in an in vitro human bronchial epithelial cell culture model. We conclude that prAAT is potentially a “biobetter” AAT product that could be made available to individuals with a wide spectrum of inflammatory disorders characterized by overly aggressive neutrophilic infiltrations.

KW - Affinity purification

KW - Alpha-1 antitrypsin

KW - Elastase

KW - HBE cell culture

KW - Oxidation resistance

KW - Transient expression

UR - http://www.scopus.com/inward/record.url?scp=85045058808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045058808&partnerID=8YFLogxK

U2 - 10.1016/j.freeradbiomed.2018.03.015

DO - 10.1016/j.freeradbiomed.2018.03.015

M3 - Article

VL - 120

SP - 303

EP - 310

JO - Free Radical Biology and Medicine

JF - Free Radical Biology and Medicine

SN - 0891-5849

ER -